HK1011351A1 - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
HK1011351A1
HK1011351A1 HK98112039A HK98112039A HK1011351A1 HK 1011351 A1 HK1011351 A1 HK 1011351A1 HK 98112039 A HK98112039 A HK 98112039A HK 98112039 A HK98112039 A HK 98112039A HK 1011351 A1 HK1011351 A1 HK 1011351A1
Authority
HK
Hong Kong
Prior art keywords
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
HK98112039A
Other languages
English (en)
Inventor
Hiroshi Hasegawa
Kazuo Isomae
Takeshi Kotsugai
Noriaki Shioiri
Kumiko Sekine
Naokata Taido
Susumu Sato
Tadayuki Kuraishi
Original Assignee
Ss Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ss Pharmaceutical Co filed Critical Ss Pharmaceutical Co
Publication of HK1011351A1 publication Critical patent/HK1011351A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98112039A 1990-10-19 1998-11-16 Quinoline derivatives HK1011351A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28109490 1990-10-19
JP28109390 1990-10-19

Publications (1)

Publication Number Publication Date
HK1011351A1 true HK1011351A1 (en) 1999-07-09

Family

ID=26554052

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98112039A HK1011351A1 (en) 1990-10-19 1998-11-16 Quinoline derivatives

Country Status (8)

Country Link
US (2) US5190951A (xx)
EP (2) EP0987262A1 (xx)
KR (1) KR100206200B1 (xx)
CA (1) CA2053640C (xx)
DE (1) DE69132519T2 (xx)
ES (1) ES2156853T3 (xx)
HK (1) HK1011351A1 (xx)
SG (1) SG44523A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
ATE209036T1 (de) * 1995-06-15 2001-12-15 Upjohn Co Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel
EP1086102A1 (en) * 1998-06-10 2001-03-28 Arena Pharmaceuticals, Inc. Acetylcholine enhancers
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
US6800625B2 (en) 2002-06-19 2004-10-05 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
WO2007073283A1 (en) * 2005-12-20 2007-06-28 Astrazeneca Ab Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
AR067028A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Compuestos y usos de los mismos 849
TW200904817A (en) * 2007-06-19 2009-02-01 Astrazeneca Ab Compounds and uses thereof
BR112012019923A2 (pt) 2010-02-09 2016-08-09 Univ Johns Hopkins métodos e composições para melhorar a função cognitiva
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
CN102875602B (zh) * 2012-10-25 2015-05-20 江苏神龙药业有限公司 一种米诺膦酸水合物的制备方法
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2015095783A1 (en) 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
CN112608326B (zh) * 2021-01-22 2021-10-01 河南大学 呋喃并[2,3-b]喹啉-3,4（2H,9H)-二酮衍生物、其制备方法及应用
CN114989180B (zh) * 2022-05-26 2024-06-04 广东海洋大学 杨叶肖槿内生真菌来源的化合物及其制备方法与应用
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2507076B2 (ja) * 1989-08-11 1996-06-12 株式会社クボタ カ―ド式自動販売機
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5240934A (en) * 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives

Also Published As

Publication number Publication date
DE69132519D1 (de) 2001-03-01
DE69132519T2 (de) 2001-06-13
EP0987262A1 (en) 2000-03-22
CA2053640A1 (en) 1992-04-20
KR100206200B1 (ko) 1999-07-01
CA2053640C (en) 2001-12-25
EP0481429A3 (en) 1992-08-19
KR920008024A (ko) 1992-05-27
US5190951A (en) 1993-03-02
SG44523A1 (en) 1997-12-19
US5300517A (en) 1994-04-05
ES2156853T3 (es) 2001-08-01
EP0481429B1 (en) 2001-01-24
EP0481429A2 (en) 1992-04-22

Similar Documents

Publication Publication Date Title
GB9108547D0 (en) Quinoline derivatives
EP0481429A3 (en) Quinoline derivatives
EP0440950A3 (en) Halogenallyl-azolyl derivatives
HU912356D0 (en) Rapacmycine derivatives
EP0470466A3 (en) Halogenalkyl-azolyl derivatives
IL96819A0 (en) Azaoxindole derivatives
HRP930485A2 (en) Hiv-inhibiting benzenacetamide derivatives
IL99576A0 (en) Triazacyclohexane derivatives
ZA915595B (en) Carbostyril derivatives
EP0485984A3 (en) Diarylmethoxypiperidine derivatives
IL101627A0 (en) 4-aryl-3-(heteroarylureido)quinoline derivatives
OA09670A (en) Carbo-nucleoside derivatives
EP0440949A3 (en) Halogenallyl-azolyl derivatives
GB9126438D0 (en) New quinoline derivatives
AP9100308A0 (en) Carboxymethylcyclopropane derivatives
EP0453883A3 (en) 2-amino-4-trichloropyridine derivatives
IE901869L (en) Quinoline derivatives
GB2249094B (en) Hetero-imidazodiazepine derivatives
IE900817L (en) Tetrahydroquinoline derivatives
EP0449346A3 (en) 4-piperidinyl-ergoline derivatives
EG19474A (en) Nitroenamine derivatives
EG19362A (en) Azoaxindole derivatives
GB9201427D0 (en) Quinoline derivatives
IE890572L (en) Quinoline derivatives
ZA901927B (en) Quinoline derivatives

Legal Events

Date Code Title Description
PF Patent in force
AS Change of ownership

Owner name: BIOMEDIX CO., LTD.

Free format text: FORMER OWNER(S): SS PHARMACEUTICAL CO., LTD

CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20071015